Abstract
The role of the cell adhesion molecules, LFA-1 and ICAM-1, in intraocular tumor rejection was examined using four different syngeneic intraocular regressor tumors and four different inbred mouse strains. All four tumors undergo T cell-dependent immune rejection in the syngeneic host. Two of the tumors, D5.1G4 melanoma and P91 mastocytoma, undergo rejection by a cytotoxic T lymphocyte-like immune process. The other two tumors, UV5C25 fibrosarcoma and 124E2 melanoma, are rejected by a process that appears to be mediated by delayed-type hypersensitivity. Systemic administration of anti-LFA-1 prevented the rejection of all four categories of tumors. By contrast, similar in vivo treatment with anti-ICAM-1 antibody did not inhibit tumor rejection. The effect of anti-LFA-1 and anti-ICAM-1 antibody treatment on the rejection of metastases arising from intraocular P91 tumors was also examined and found to be highly dependent upon normal LFA-1 function since antibody treatment with anti-LFA-1 prevented the rejection of metastases. Treatment with anti-ICAM-1 antibody alone had no appreciable effect on the rejection of metastases. The results from this study indicate that the expression and function of LFA-1 is crucial for the generation of immune responses to tumor antigens originating within the eye and the expression of tumor immunity within the eye and at distant sites.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 719-726 |
| Number of pages | 8 |
| Journal | Current Eye Research |
| Volume | 14 |
| Issue number | 8 |
| DOIs | |
| State | Published - 1995 |
Fingerprint
Keywords
- Cell adhesion molecules
- Intercellular adhesion molecule-1 (ICAM-1)
- Leukocyte function antigen-1 (LFA-1)
- Mouse
- T cells
- Tumor metastasis
ASJC Scopus subject areas
- Ophthalmology
- Sensory Systems
- Cellular and Molecular Neuroscience
Cite this
Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases. / Li, Xiao Yan; Mayhew, Elizabeth; Niederkorn, Jerry Y.
In: Current Eye Research, Vol. 14, No. 8, 1995, p. 719-726.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases
AU - Li, Xiao Yan
AU - Mayhew, Elizabeth
AU - Niederkorn, Jerry Y.
PY - 1995
Y1 - 1995
N2 - The role of the cell adhesion molecules, LFA-1 and ICAM-1, in intraocular tumor rejection was examined using four different syngeneic intraocular regressor tumors and four different inbred mouse strains. All four tumors undergo T cell-dependent immune rejection in the syngeneic host. Two of the tumors, D5.1G4 melanoma and P91 mastocytoma, undergo rejection by a cytotoxic T lymphocyte-like immune process. The other two tumors, UV5C25 fibrosarcoma and 124E2 melanoma, are rejected by a process that appears to be mediated by delayed-type hypersensitivity. Systemic administration of anti-LFA-1 prevented the rejection of all four categories of tumors. By contrast, similar in vivo treatment with anti-ICAM-1 antibody did not inhibit tumor rejection. The effect of anti-LFA-1 and anti-ICAM-1 antibody treatment on the rejection of metastases arising from intraocular P91 tumors was also examined and found to be highly dependent upon normal LFA-1 function since antibody treatment with anti-LFA-1 prevented the rejection of metastases. Treatment with anti-ICAM-1 antibody alone had no appreciable effect on the rejection of metastases. The results from this study indicate that the expression and function of LFA-1 is crucial for the generation of immune responses to tumor antigens originating within the eye and the expression of tumor immunity within the eye and at distant sites.
AB - The role of the cell adhesion molecules, LFA-1 and ICAM-1, in intraocular tumor rejection was examined using four different syngeneic intraocular regressor tumors and four different inbred mouse strains. All four tumors undergo T cell-dependent immune rejection in the syngeneic host. Two of the tumors, D5.1G4 melanoma and P91 mastocytoma, undergo rejection by a cytotoxic T lymphocyte-like immune process. The other two tumors, UV5C25 fibrosarcoma and 124E2 melanoma, are rejected by a process that appears to be mediated by delayed-type hypersensitivity. Systemic administration of anti-LFA-1 prevented the rejection of all four categories of tumors. By contrast, similar in vivo treatment with anti-ICAM-1 antibody did not inhibit tumor rejection. The effect of anti-LFA-1 and anti-ICAM-1 antibody treatment on the rejection of metastases arising from intraocular P91 tumors was also examined and found to be highly dependent upon normal LFA-1 function since antibody treatment with anti-LFA-1 prevented the rejection of metastases. Treatment with anti-ICAM-1 antibody alone had no appreciable effect on the rejection of metastases. The results from this study indicate that the expression and function of LFA-1 is crucial for the generation of immune responses to tumor antigens originating within the eye and the expression of tumor immunity within the eye and at distant sites.
KW - Cell adhesion molecules
KW - Intercellular adhesion molecule-1 (ICAM-1)
KW - Leukocyte function antigen-1 (LFA-1)
KW - Mouse
KW - T cells
KW - Tumor metastasis
UR - http://www.scopus.com/inward/record.url?scp=0029159980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029159980&partnerID=8YFLogxK
U2 - 10.3109/02713689508998500
DO - 10.3109/02713689508998500
M3 - Article
C2 - 8529408
AN - SCOPUS:0029159980
VL - 14
SP - 719
EP - 726
JO - Current Eye Research
JF - Current Eye Research
SN - 0271-3683
IS - 8
ER -